Construction of the state-owned Housing Development Tbk PT (PTPP) in the first quarter -2013 obtain new contracts Rp 4.5 trillion. New contracts coded PTPP has penetrated 23% of the target for the project in 2013, which amounted to Rp 19.7 trillion.
“This acquisition increased 2.5 times compared to the acquisition of new contracts to the same period last year,” said Betty Ariana PTPP Corporate Secretary in a press release on Friday (05/04/2013).
PTPP in this water dragon year targets to carve a net profit of Rp 370 billion, up 20% compared to the previous year’s target. The increase in the net income derived from the business income of 4 fields of construction, property, EPC, and investment.
Major projects which was won PTPP, among other projects JW Marriot Hotel, St Moritz, The Kencana, malls Sun Karawang, M Gold Tower, Uluwatu Hotel, Surabaya Tunjungan Plaza V, Terminal 3 of Soekarno-Hatta Airport, train tracks South Sumatra by PT KAI, and Combined Cycle Power Plant EPC project Tanjung kitbag 120 megawatts (MW).
PT Kalbe Farma, drug manufacturers and national health supplements, plans to build a dairy factory in the Cikampek, West Java. According to the Director of Finance and Corporate Secretary of Kalbe Farma, Vidjongtius, the plant cost around Rp 300 billion. “The project started in 2014,” he said at a media gathering.
Vidjongtius said the plant will be owned by the installation of a fourth milk production Kalbe Farma. With the construction of this plant, Kalbe increase milk production capacity of 12 thousand tons to 24 thousand tons per year.
Funds to build the plant will be met from capital expenditure Kalbe Farma in 2013, which reached Rp 1.5 trillion. According Vidjongtius, until the first half, the company has spent at least 40 percent of the annual capital expenditure. “The new plant is expected to support business growth in the future,” he said.
In 2012, Kalbe has completed the construction of dairy factory in Sukabumi, West Java. This plant is the result of cooperation with PT Milko Beverage Industry. Kalbe, which poured an investment of Rp 154 billion, became the majority owner with 51 percent parts.
Throughout 2013, Kalbe targeting revenue growth and net income by 18 percent. That figure is above the growth of the pharmaceutical industry which reached 15 percent. In 2012, Kalbe Farma pocketed a net profit of Rp 1.73 trillion and Rp 13.6 trillion in net sales. Thus, the company targets a net profit of Rp 2.04 trillion and Rp 16 trillion in net sales in 2013.